Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
Mesoblast director Gregory George has increased his overall indirect stake in the company through on-market purchases of American Depositary Shares and ordinary shares made by related parties James and Grant George. The transactions, totaling about US$11.43 million, significantly lift the family’s indirect holdings in Mesoblast, signaling strengthened insider confidence and potentially reinforcing market perception of the company’s long-term prospects.
Following the trades on 9 and 10 April 2026, indirect holdings associated with Gregory George rose to more than 12.8 million ordinary shares and 14.4 million ADSs, while his direct holdings remained unchanged. The absence of any disposals in the disclosure underscores a net increase in insider exposure to Mesoblast’s equity, a development that existing and prospective shareholders may interpret as a positive indicator of management’s view on future value.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.23 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company listed on the ASX. It is focused on developing and commercializing cell-based and regenerative medicine therapies, with its equity traded both as ordinary shares and as American Depositary Shares, expanding its reach to international investors.
Average Trading Volume: 4,151,861
Technical Sentiment Signal: Sell
Current Market Cap: A$2.8B
Learn more about MSB stock on TipRanks’ Stock Analysis page.